Federal Circuit Upholds Decision in Heart Valve IP Suit Against Edwards

By Editorial Team

The Federal Circuit has affirmed a decision that Edwards Lifesciences will not face infringement litigation from Aortic Innovations regarding heart valve transplant technology. The ruling was made on Monday, following a legal battle over the intellectual property rights related to heart valve technology.

Edwards Lifesciences was accused of infringing on several patents owned by Aortic Innovations, including patents related to methods for aortic repair and replacement, devices for endovascular aortic repair, and transcatheter valve repair technology.

The case involved prominent law firms such as Knobbe Martens, McKool Smith, and Weil Gotshal representing the parties. The litigation also saw involvement from government agencies like the Patent Trial and Appeal Board, the U.S. Court of Appeals for the Federal Circuit, and the U.S. District Court for the Western District of Tennessee.

Among the patents in question were:

• 10,881,538 - Method for aortic repair and aortic replacement
• 10,966,846 - Device for endovascular aortic repair
• 10,987,236 - Transcatheter aortic valve repair having improved paravalvular seal
• 11,129,735 - Transcatheter valve repair having improved paravalvular seal

The decision by the Federal Circuit to uphold the ruling not to revive the IP suit against Edwards Lifesciences marks a significant development in the legal landscape surrounding heart valve technology. The court's decision is likely to have implications for future cases involving similar intellectual property disputes in the medical technology sector.